-
1 Comment
DaShenLin Pharmaceutical Group Co., Ltd is currently in a long term downtrend where the price is trading 28.5% below its 200 day moving average.
From a valuation standpoint, the stock is 55.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.3.
DaShenLin Pharmaceutical Group Co., Ltd's total revenue rose by 27.4% to $4B since the same quarter in the previous year.
Its net income has increased by 55.2% to $272M since the same quarter in the previous year.
Finally, its free cash flow grew by 41.3% to $688M since the same quarter in the previous year.
Based on the above factors, DaShenLin Pharmaceutical Group Co., Ltd gets an overall score of 4/5.
| CurrencyCode | CNY |
|---|---|
| ISIN | CNE100002RG2 |
| Exchange | SHG |
| Sector | Healthcare |
| Industry | Biotechnology |
| PE Ratio | 23.27 |
|---|---|
| Target Price | 24.41 |
| Beta | 0.6 |
| Market Cap | 20B |
| Dividend Yield | None |
DaShenLin Pharmaceutical Group Co., Ltd. manufactures, wholesales, and retails pharmaceutical products in China. It provides Chinese and western patent medicines, ginseng tonic medicinal materials and Chinese herbal pieces, health care products, medical equipment, and other commodities. The company was incorporated in 1999 and is based in Guangzhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 603233.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
